Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04720599 · ClinicalTrials.gov registry record
Clinical Evaluation of ExoDx Prostate(IntelliScore) in Men Presenting for Initial Prostate Biopsy
A clinical trial, sponsored by Exosome Diagnostics.
- Completed
- Registry status
- 120
- Enrollment target
NCT04720599 is a clinical trial that has completed, run by Exosome Diagnostics. The registered enrollment target is 120 participants.
The verdict
NCT04720599 has completed, sponsored by Exosome Diagnostics.
- COMPLETED
- Registry status
- 120 participants
- Enrollment target
Study Summary
The study described here is being conducted to prospectively confirm the performance of the ExoDx Prostate gene expression assay in patients presenting for an initial prostate biopsy and support of CE-marking the test for a European Union Launch.
Interventions
- DIAGNOSTIC_TEST ExoDx Prostate(IntelliScore)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2020-06-01 |
| Est. Completion | 2021-06-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04720599
The ClinicalTrials.gov registry entry for NCT04720599 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Exosome Diagnostics, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ExoDx Prostate(IntelliScore) is the first listed.
NCT04720599 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04720599 about?
NCT04720599 is a clinical study titled "Clinical Evaluation of ExoDx Prostate(IntelliScore) in Men Presenting for Initial Prostate Biopsy". The study described here is being conducted to prospectively confirm the performance of the ExoDx Prostate gene expression assay in patients presenting for an initial prostate biopsy and support of CE-marking the test for a European Union Launch.
What is the current status of trial NCT04720599?
This trial is currently completed. The enrollment target is 120 participants. The study started on 2020-06-01. Estimated completion is 2021-06-01.
What interventions are being tested in trial NCT04720599?
The interventions under investigation include: ExoDx Prostate(IntelliScore) (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT04720599?
This trial is sponsored by Exosome Diagnostics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.